

Val J Lowe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5082494/publications.pdf>

Version: 2024-02-01

265
papers

14,456
citations

20759

60
h-index

29081

104
g-index

268
all docs

268
docs citations

268
times ranked

13530
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 205-216.	0.4	581
2	An autoradiographic evaluation of AV-1451 Tau PET in dementia. <i>Acta Neuropathologica Communications</i> , 2016, 4, 58.	2.4	388
3	Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau and amyloid-positron emission tomography. <i>Alzheimer's and Dementia</i> , 2018, 14, 989-997.	0.4	386
4	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 540-557.	3.3	348
5	Longitudinal tau PET in ageing and Alzheimer's disease. <i>Brain</i> , 2018, 141, 1517-1528.	3.7	309
6	Age, Sex, and APOE ϵ 4 Effects on Memory, Brain Structure, and β -Amyloid Across the Adult Life Span. <i>JAMA Neurology</i> , 2015, 72, 511.	4.5	305
7	Age-specific population frequencies of cerebral β -amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2014, 13, 997-1005.	4.9	297
8	Clinicopathologic and β -C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. <i>Brain</i> , 2015, 138, 1370-1381.	3.7	270
9	Age-specific and sex-specific prevalence of cerebral β -amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2017, 16, 435-444.	4.9	241
10	Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. <i>Mayo Clinic Proceedings</i> , 2014, 89, 926-933.	1.4	240
11	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2316.	3.8	223
12	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. <i>Brain</i> , 2015, 138, 761-771.	3.7	222
13	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. <i>Brain</i> , 2018, 141, 271-287.	3.7	218
14	Comparison of β -F-FDG and PiB PET in Cognitive Impairment. <i>Journal of Nuclear Medicine</i> , 2009, 50, 878-886.	2.8	183
15	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework. <i>JAMA Neurology</i> , 2019, 76, 1174.	4.5	182
16	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. <i>Brain</i> , 2015, 138, 3747-3759.	3.7	170
17	Comparison of Positron Emission Tomography, Computed Tomography, and Endoscopic Ultrasound in the Initial Staging of Patients with Esophageal Cancer. <i>Molecular Imaging and Biology</i> , 2005, 7, 422-430.	1.3	163
18	Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015, 2, e161.	3.1	163

#	ARTICLE	IF	CITATIONS
19	Transplanted Senescent Cells Induce an Osteoarthritis-Like Condition in Mice. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, glw154.	1.7	163
20	Multimodality imaging characteristics of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2012, 33, 2091-2105.	1.5	162
21	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. <i>Cortex</i> , 2017, 97, 143-159.	1.1	162
22	Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. <i>JAMA Neurology</i> , 2016, 73, 85.	4.5	160
23	Multisite study of the relationships between <i>antemortem</i> [¹¹ C]PIB-PET Centiloid values and <i>postmortem</i> measures of Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 205-216.	0.4	155
24	¹⁸ F-AV-1451 tau and ¹²⁵ I-amyloid positron emission tomography imaging in dementia with Lewy bodies. <i>Annals of Neurology</i> , 2017, 81, 58-67.	2.8	152
25	Association of Excessive Daytime Sleepiness With Longitudinal ¹²⁵ I-Amyloid Accumulation in Elderly Persons Without Dementia. <i>JAMA Neurology</i> , 2018, 75, 672.	4.5	150
26	Dementia with Lewy bodies. <i>Neurology</i> , 2014, 83, 801-809.	1.5	143
27	Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease. <i>Practical Radiation Oncology</i> , 2018, 8, 28-39.	1.1	140
28	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. <i>Annals of Neurology</i> , 2017, 82, 706-718.	2.8	136
29	[¹⁸ F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. <i>Movement Disorders</i> , 2017, 32, 124-133.	2.2	136
30	The evolution of primary progressive apraxia of speech. <i>Brain</i> , 2014, 137, 2783-2795.	3.7	134
31	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. <i>Cortex</i> , 2015, 69, 220-236.	1.1	133
32	The bivariate distribution of amyloid- ¹²⁵ I and tau: relationship with established neurocognitive clinical syndromes. <i>Brain</i> , 2019, 142, 3230-3242.	3.7	129
33	White matter hyperintensities: relationship to amyloid and tau burden. <i>Brain</i> , 2019, 142, 2483-2491.	3.7	126
34	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). <i>Acta Neuropathologica</i> , 2017, 133, 705-715.	3.9	125
35	[¹⁸ F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. <i>Acta Neuropathologica</i> , 2016, 132, 931-933.	3.9	116
36	Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. <i>JAMA Neurology</i> , 2018, 75, 970.	4.5	116

#	ARTICLE	IF	CITATIONS
37	Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research. <i>Alzheimer's and Dementia</i> , 2021, 17, 1554-1574.	0.4	114
38	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. <i>JAMA Neurology</i> , 2021, 78, 1108.	4.5	114
39	Performance of plasma phosphorylated tau 181 and 217 in the community. <i>Nature Medicine</i> , 2022, 28, 1398-1405.	15.2	114
40	Tau-positron emission tomography correlates with neuropathology findings. <i>Alzheimer's and Dementia</i> , 2020, 16, 561-571.	0.4	113
41	¹⁸ F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. <i>Neurobiology of Aging</i> , 2014, 35, 2096-2106.	1.5	108
42	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. <i>JAMA Neurology</i> , 2017, 74, 718.	4.5	107
43	Prosodic and phonetic subtypes of primary progressive apraxia of speech. <i>Brain and Language</i> , 2018, 184, 54-65.	0.8	106
44	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 56-64.	4.9	104
45	Early Postmenopausal Transdermal ¹⁷ β-Estradiol Therapy and Amyloid-β Deposition. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 547-556.	1.2	94
46	Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Detected by ¹¹ C-Choline Positron Emission Tomography/Computerized Tomography. <i>Journal of Urology</i> , 2015, 193, 111-116.	0.2	92
47	¹⁸ F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies. <i>Journal of Nuclear Medicine</i> , 2017, 58, 632-638.	2.8	91
48	Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 21-30.	1.2	86
49	Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. <i>Brain Communications</i> , 2020, 2, fcaa068.	1.5	81
50	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1005-1014.	0.4	80
51	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. <i>Neurobiology of Disease</i> , 2019, 121, 327-337.	2.1	79
52	Predicting future rates of tau accumulation on PET. <i>Brain</i> , 2020, 143, 3136-3150.	3.7	74
53	Association of hypometabolism and amyloid levels in aging, normal subjects. <i>Neurology</i> , 2014, 82, 1959-1967.	1.5	73
54	[¹⁸ F]AV-1451 tau-PET and primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 83, 599-611. 2.8	2.8	73

#	ARTICLE	IF	CITATIONS
55	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. <i>Brain</i> , 2019, 142, 1134-1147.	3.7	72
56	Effect of intellectual enrichment on AD biomarker trajectories. <i>Neurology</i> , 2016, 86, 1128-1135.	1.5	71
57	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. <i>JAMA Neurology</i> , 2019, 76, 95.	4.5	69
58	Amyloid- β^2 deposition and regional grey matter atrophy rates in dementia with Lewy bodies. <i>Brain</i> , 2016, 139, 2740-2750.	3.7	68
59	Entorhinal cortex tau, amyloid- β^2 , cortical thickness and memory performance in non-demented subjects. <i>Brain</i> , 2019, 142, 1148-1160.	3.7	68
60	Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. <i>Brain</i> , 2021, 144, 278-287.	3.7	68
61	[¹⁸ F]AV β 1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 83, 248-257.	2.8	67
62	FDG-PET in tau-negative amnesic dementia resembles that of autopsy-proven hippocampal sclerosis. <i>Brain</i> , 2018, 141, 1201-1217.	3.7	67
63	β^2 -Amyloid PET and neuropathology in dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e282-e291.	1.5	65
64	¹⁸ F-FDG PET of patients with H β 4rthle cell carcinoma. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1402-6.	2.8	64
65	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. <i>NeuroImage</i> , 2021, 224, 117433.	2.1	63
66	The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the NO neck. <i>Cancer</i> , 2001, 92, 2341-2348.	2.0	62
67	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. <i>Neurology</i> , 2019, 93, e29-e39.	1.5	62
68	β^2 -Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. <i>Neurology</i> , 2020, 95, e3257-e3268.	1.5	62
69	In vivo ¹⁸ F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. <i>Neurology</i> , 2018, 90, e947-e954.	1.5	60
70	Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. <i>NeuroImage</i> , 2017, 144, 113-127.	2.1	59
71	Multimodal Nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain. <i>Biomaterials</i> , 2014, 35, 1967-1976.	5.7	58
72	Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. <i>Journal of Controlled Release</i> , 2014, 185, 121-129.	4.8	58

#	ARTICLE	IF	CITATIONS
73	Atrial fibrillation, cognitive impairment, and neuroimaging. <i>Alzheimer's and Dementia</i> , 2016, 12, 391-398.	0.4	58
74	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. <i>JAMA Neurology</i> , 2014, 71, 1547.	4.5	57
75	Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. <i>Neurology</i> , 2018, 90, e1404-e1412.	1.5	57
76	Abnormal Fluorodeoxyglucose PET in Pulmonary Langerhans Cell Histiocytosis. <i>Chest</i> , 2009, 135, 1542-1549.	0.4	55
77	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 23, 101823.	1.4	54
78	Cortical β -amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging. <i>Translational Psychiatry</i> , 2019, 9, 123.	2.4	54
79	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 1618-1631.	1.9	53
80	Cerebral microbleeds. <i>Neurology</i> , 2019, 92, e253-e262.	1.5	53
81	Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. <i>International Psychogeriatrics</i> , 2018, 30, 245-251.	0.6	52
82	Deep learning-based brain age prediction in normal aging and dementia. <i>Nature Aging</i> , 2022, 2, 412-424.	5.3	52
83	Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. <i>European Urology</i> , 2017, 71, 340-348.	0.9	51
84	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. <i>Brain</i> , 2020, 143, 2281-2294.	3.7	51
85	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. <i>Brain and Language</i> , 2015, 142, 45-53.	0.8	49
86	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. <i>Annals of Neurology</i> , 2018, 84, 705-716.	2.8	49
87	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 927-939.	0.4	48
88	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 181-195.	1.2	48
89	Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. <i>Clinical Neuropsychologist</i> , 2017, 31, 99-117.	1.5	47
90	Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. <i>Neurology</i> , 2013, 80, 2130-2137.	1.5	46

#	ARTICLE	IF	CITATIONS
91	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. <i>NeuroImage: Clinical</i> , 2020, 25, 102152.	1.4	46
92	Influence of amyloid and <i>APOE</i> on cognitive performance in a late middle-aged cohort. <i>Alzheimer's and Dementia</i> , 2016, 12, 281-291.	0.4	45
93	Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with ¹¹ C-Choline Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging. <i>Journal of Urology</i> , 2017, 197, 129-134.	0.2	45
94	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1713-1724.	1.2	45
95	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease. <i>Cerebral Cortex</i> , 2021, 31, 1693-1706.	1.6	44
96	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. <i>Cortex</i> , 2018, 99, 358-374.	1.1	42
97	Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. <i>Brain</i> , 2018, 141, 302-317.	3.7	42
98	Increased Brain Glucose Uptake After 12 Weeks of Aerobic High-Intensity Interval Training in Young and Older Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 221-227.	1.8	41
99	Association of Apolipoprotein E ϵ 4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. <i>JAMA Network Open</i> , 2019, 2, e1913909.	2.8	41
100	¹¹ C-Choline PET/CT in Recurrent Prostate Cancer and Nonprostatic Neoplastic Processes. <i>Radiographics</i> , 2016, 36, 279-292.	1.4	40
101	Prevalence and Natural History of Superficial Siderosis. <i>Stroke</i> , 2017, 48, 3210-3214.	1.0	40
102	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. <i>Annals of Neurology</i> , 2019, 86, 866-877.	2.8	40
103	White Matter Reference Region in PET Studies of ¹¹ C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid- β Deposition. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1583-1589.	2.8	37
104	<i>APOE3</i> -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. <i>Science Translational Medicine</i> , 2021, 13, eabc9375.	5.8	37
105	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 675-685.	0.4	36
106	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. <i>Neurobiology of Aging</i> , 2015, 36, 2010-2017.	1.5	35
107	FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1609-1616.	1.2	35
108	Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 526-535.	0.4	35

#	ARTICLE	IF	CITATIONS
109	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 739-749.	1.4	34
110	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. <i>Nature Communications</i> , 2021, 12, 3452.	5.8	34
111	Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy. <i>European Urology Focus</i> , 2016, 2, 522-531.	1.6	33
112	18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. <i>NeuroImage: Clinical</i> , 2018, 18, 897-902.	1.4	33
113	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. <i>Brain</i> , 2019, 142, 2466-2482.	3.7	33
114	MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2019, 34, 105-113.	2.2	33
115	The pimple sign of progressive supranuclear palsy syndrome. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 180-185.	1.1	32
116	<i>MAPT</i> haplotype H1G is associated with increased risk of dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2016, 12, 1297-1304.	0.4	32
117	Predicting Progression to Mild Cognitive Impairment. <i>Annals of Neurology</i> , 2019, 85, 155-160.	2.8	32
118	Sensitivity–Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration. <i>Annals of Neurology</i> , 2020, 88, 1009-1022.	2.8	32
119	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 199.	3.0	32
120	<i>APOE</i> ϵ 4 influences β -amyloid deposition in primary progressive aphasia and speech apraxia. <i>Alzheimer's and Dementia</i> , 2014, 10, 630-636.	0.4	31
121	BBBomics-Human Blood Brain Barrier Transcriptomics Hub. <i>Frontiers in Neuroscience</i> , 2016, 10, 71.	1.4	31
122	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. <i>NeuroImage: Clinical</i> , 2018, 19, 939-947.	1.4	31
123	Cerebral microbleed incidence, relationship to amyloid burden. <i>Neurology</i> , 2020, 94, e190-e199.	1.5	31
124	<sc>NIA–AA</sc> Alzheimer's Disease Framework: Clinical Characterization of Stages. <i>Annals of Neurology</i> , 2021, 89, 1145-1156.	2.8	31
125	Initial Results of a Phase 2 Trial of 18F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1383-1395.	0.4	31
126	Peptide Carrier-Mediated Non-Covalent Delivery of Unmodified Cisplatin, Methotrexate and Other Agents via Intravenous Route to the Brain. <i>PLoS ONE</i> , 2014, 9, e97655.	1.1	30

#	ARTICLE	IF	CITATIONS
127	Comparison of [¹⁸ F]Flutemetamol and [¹¹ C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. <i>NeuroImage: Clinical</i> , 2017, 16, 295-302.	1.4	30
128	A robust biomarker of large-scale network failure in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 152-161.	1.2	29
129	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. <i>Brain and Language</i> , 2019, 197, 104676.	0.8	29
130	Prediction of MGMT Status for Glioblastoma Patients Using Radiomics Feature Extraction From 18F-DOPA-PET Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1339-1346.	0.4	29
131	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. <i>Neurology</i> , 2020, 94, e1793-e1802.	1.5	28
132	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 633-643.	1.2	27
133	Multimorbidity and neuroimaging biomarkers among cognitively normal persons. <i>Neurology</i> , 2016, 86, 2077-2084.	1.5	27
134	Joint associations of β -amyloidosis and cortical thickness with cognition. <i>Neurobiology of Aging</i> , 2018, 65, 121-131.	1.5	27
135	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 3-9.	1.1	27
136	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. <i>Neurology</i> , 2020, 95, e23-e34.	1.5	27
137	Association of Initial β -Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021, 78, 217.	4.5	27
138	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. <i>NeuroImage: Clinical</i> , 2021, 31, 102754.	1.4	27
139	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. <i>Alzheimer's and Dementia</i> , 2014, 10, 779-789.	0.4	26
140	Contributions of imprecision in $\langle \text{PET} \rangle$ vs $\langle \text{MRI} \rangle$ rigid registration to imprecision in amyloid $\langle \text{PET} \rangle$ $\langle \text{SUVr} \rangle$ measurements. <i>Human Brain Mapping</i> , 2017, 38, 3323-3336.	1.9	26
141	Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[¹⁸ F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 137, 583-591.	1.4	26
142	The Relationship Between Dopamine Neurotransmitter Dynamics and the Blood-Oxygen-Level-Dependent (BOLD) Signal: A Review of Pharmacological Functional Magnetic Resonance Imaging. <i>Frontiers in Neuroscience</i> , 2018, 12, 238.	1.4	26
143	¹⁸ F-AV-1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. <i>Movement Disorders</i> , 2019, 34, 344-352.	2.2	26
144	Inhibition of Cdc20 suppresses the metastasis in triple negative breast cancer (TNBC). <i>Breast Cancer</i> , 2021, 28, 1073-1086.	1.3	26

#	ARTICLE	IF	CITATIONS
145	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. <i>Brain</i> , 2021, 144, 3212-3225.	3.7	26
146	Preparation and Preliminary Evaluation of ⁶³ Zn-Zinc Citrate as a Novel PET Imaging Biomarker for Zinc. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1348-1354.	2.8	25
147	Clinical significance of incidental [18F]FDG uptake in the gastrointestinal tract on PET/CT imaging: a retrospective cohort study. <i>BMC Gastroenterology</i> , 2016, 16, 125.	0.8	25
148	Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects. <i>EJNMMI Research</i> , 2017, 7, 90.	1.1	25
149	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 355.	1.7	25
150	Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 179-191.	0.6	25
151	Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1019-1029.	1.2	24
152	Tau-negative amnesic dementia masquerading as Alzheimer disease dementia. <i>Neurology</i> , 2018, 90, e940-e946.	1.5	24
153	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. <i>NeuroImage</i> , 2021, 238, 118259.	2.1	24
154	Role of β -Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2015, 72, 1475.	4.5	23
155	Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. <i>Abdominal Radiology</i> , 2018, 43, 2391-2399.	1.0	23
156	Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1345-1352.	1.2	23
157	18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis—A Multicenter Retrospective Study. <i>Cancers</i> , 2019, 11, 700.	1.7	23
158	Brain imaging measurements of fibrillar amyloid β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the <i>APOE</i> μ 4 allele. <i>Alzheimer's and Dementia</i> , 2020, 16, 598-609.	0.4	23
159	First PET Imaging Studies With ⁶³ Zn-Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease. <i>Molecular Imaging</i> , 2016, 15, 153601211667379.	0.7	22
160	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. <i>Neurology</i> , 2016, 87, 691-698.	1.5	22
161	Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 281-290.	1.2	22
162	Association of Longitudinal β -Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. <i>JAMA Network Open</i> , 2019, 2, e1916439.	2.8	22

#	ARTICLE	IF	CITATIONS
163	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2016, 45, 107-108.	1.5	21
164	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. <i>Annals of Neurology</i> , 2021, 89, 520-533.	2.8	21
165	Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6376-6383.	3.2	21
166	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. <i>Neurobiology of Aging</i> , 2016, 46, 32-42.	1.5	20
167	The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 34-40.	1.1	20
168	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1109-1117.	1.2	19
169	Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 210-216.	1.2	19
170	Multimodal neuroimaging relationships in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 56-61.	1.1	19
171	Cerebrospinal fluid dynamics disorders. <i>Neurology</i> , 2019, 93, e2237-e2246.	1.5	19
172	¹ H-MRS metabolites and rate of ¹² I-amyloid accumulation on serial PET in clinically normal adults. <i>Neurology</i> , 2017, 89, 1391-1399.	1.5	18
173	Confirmation of ¹²³ I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1628-1635.	2.8	18
174	Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults. <i>Neurology</i> , 2020, 94, e1571-e1579.	1.5	18
175	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer's pathophysiology. <i>Acta Neuropathologica Communications</i> , 2021, 9, 48.	2.4	18
176	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2021, 105, 252-261.	1.5	18
177	Assessment of Lymphoma Therapy Using (18)F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2002, 43, 1028-30.	2.8	18
178	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 101-109.	0.5	17
179	¹⁸ F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. <i>Brain Communications</i> , 2020, 2, fcaa040.	1.5	17
180	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 87, 556-567.	2.8	17

#	ARTICLE	IF	CITATIONS
181	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 707-721.	1.7	17
182	Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia</i> , 2023, 19, 4498-4506.	0.4	17
183	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. <i>Neurology: Genetics</i> , 2016, 2, e85.	0.9	16
184	The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 877-883.	1.7	16
185	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. <i>Neurology</i> , 2017, 89, 2039-2048.	1.5	15
186	Relationships between $\hat{1}^2$ -amyloid and tau in an elderly population: An accelerated failure time model. <i>NeuroImage</i> , 2021, 242, 118440.	2.1	15
187	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. <i>Brain Communications</i> , 2022, 4, fcac013.	1.5	15
188	Microbleeds in the logopenic variant of primary progressive aphasia. <i>Alzheimer's and Dementia</i> , 2014, 10, 62-66.	0.4	14
189	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. <i>British Journal of Anaesthesia</i> , 2020, 124, 594-602.	1.5	14
190	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. <i>Acta Neuropathologica Communications</i> , 2022, 10, 16.	2.4	14
191	A longitudinal investigation of \hat{A}^2 , anxiety, depression, and mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2022, 18, 1824-1831.	0.4	14
192	Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using $\langle \sup \rangle 11 \langle /sup \rangle$ C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging. <i>Journal of Urology</i> , 2018, 199, 726-733.	0.2	13
193	$\hat{1}^2$ -Amyloid PET and $\langle \sup \rangle 123 \langle /sup \rangle$ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. <i>Neurology</i> , 2021, 96, .	1.5	13
194	White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. <i>Brain Communications</i> , 2021, 3, fcab076.	1.5	13
195	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. <i>Neurology</i> , 2020, 95, e3190-e3202.	1.5	13
196	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2021, 32, 102850.	1.4	13
197	Perceived Misinterpretation Rates in Oncologic $\langle \sup \rangle 18 \langle /sup \rangle$ F-FDG PET/CT Studies: A Survey of Referring Physicians. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1925-1929.	2.8	12
198	NMDA receptor encephalitis causing reversible caudate changes on MRI and PET imaging. <i>Neurology: Clinical Practice</i> , 2014, 4, 470-473.	0.8	12

#	ARTICLE	IF	CITATIONS
199	Variants in <i>PPP2R2B</i> and <i>IGF2BP3</i> are associated with higher tau deposition. <i>Brain Communications</i> , 2020, 2, fcaa159.	1.5	12
200	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. <i>Pancreatology</i> , 2020, 20, 1115-1122.	0.5	12
201	loflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. <i>Journal of Neurology</i> , 2020, 267, 2603-2611.	1.8	12
202	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. <i>Brain Communications</i> , 2021, 3, fcab182.	1.5	12
203	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. <i>Brain Communications</i> , 2022, 4, fcac017.	1.5	12
204	Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease. <i>Neurology</i> , 2022, 98, .	1.5	12
205	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 99, 11-18.	1.5	11
206	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. <i>Neurobiology of Aging</i> , 2021, 108, 90-98.	1.5	11
207	Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. <i>Brain Communications</i> , 2021, 3, fcaa238.	1.5	11
208	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2022, 37, 1256-1264.	2.2	11
209	Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. <i>NeuroImage: Clinical</i> , 2016, 11, 90-98.	1.4	10
210	Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 2274-2281.	1.3	10
211	The influence of β^2 -amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. <i>Neurology</i> , 2019, 92, e710-e722.	1.5	10
212	High-Density Lipoprotein Mimetic Peptide 4F Efficiently Crosses the Blood-Brain Barrier and Modulates Amyloid- β^2 Distribution between Brain and Plasma. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 308-316.	1.3	10
213	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid- β^2 PET Signal. <i>Neurology</i> , 2021, 97, e1799-e1808.	1.5	10
214	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. <i>Journal of Neuro-Oncology</i> , 2018, 136, 373-378.	1.4	9
215	Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values. <i>Scientific Reports</i> , 2018, 8, 7421.	1.6	9
216	Association of Cortical and Subcortical β^2 -Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2021, 33, 64-71.	0.9	9

#	ARTICLE	IF	CITATIONS
217	Cerebral Microbleeds. <i>Stroke</i> , 2021, 52, 2347-2355.	1.0	9
218	Brain Metabolic Changes with Longitudinal Transcutaneous Afferent Patterned Stimulation in Essential Tremor Subjects. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 10, 52.	1.1	9
219	The <i>A20/TNFAIP3-CDC20-CASP1</i> Axis Promotes Inflammation-mediated Metastatic Disease in Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2022, 42, 681-695.	0.5	9
220	1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2022, 112, 16-26.	1.5	9
221	Ex Vivo Cell Therapy by Ectopic Hepatocyte Transplantation Treats the Porcine Tyrosinemia Model of Acute Liver Failure. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 738-750.	1.8	8
222	¹¹ C-choline positron emission tomography/computed tomography for detection of disease relapse in patients with history of biochemically recurrent prostate cancer and prostate-specific antigen ≥ 0.1 ng/ml. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 358.	0.3	8
223	Medial Temporal Atrophy in Posterior Cortical Atrophy and Its Relationship to the Cingulate Island Sign. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 491-498.	1.2	8
224	Uptake of AV-1451 in meningiomas. <i>Annals of Nuclear Medicine</i> , 2017, 31, 736-743.	1.2	7
225	Longitudinal Amyloid- β^2 PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 377-389.	1.2	7
226	Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. <i>Neurobiology of Aging</i> , 2021, 110, 27-36.	1.5	7
227	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer's disease: a series of clinical cases. <i>Journal of Neurology</i> , 2022, 269, 4110-4128.	1.8	7
228	Posterior cortical atrophy: Primary occipital variant. <i>European Journal of Neurology</i> , 2022, 29, 2138-2143.	1.7	7
229	Esophageal cancer and head and neck cancer. <i>Seminars in Roentgenology</i> , 2002, 37, 140-150.	0.2	6
230	Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. <i>Neurocase</i> , 2020, 26, 259-263.	0.2	6
231	FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cNO. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 164, 1230-1239.	1.1	6
232	Radium-223 in the Third-Line Setting in Metastatic Castration-Resistant Prostate Cancer: Impact of Concomitant Use of Enzalutamide on Overall Survival (OS) and Predictors of Improved OS. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 223-229.	0.9	6
233	Design, Synthesis, and Preliminary Evaluation of [⁶⁸ Ga]Ga-NOTA-Insulin as a PET Probe in an Alzheimer's Disease Mouse Model. <i>Bioconjugate Chemistry</i> , 2022, 33, 892-906.	1.8	6
234	Dosimetric impact of amino acid positron emission tomography imaging for target delineation in radiation treatment planning for high-grade gliomas. <i>Physics and Imaging in Radiation Oncology</i> , 2018, 6, 94-100.	1.2	5

#	ARTICLE	IF	CITATIONS
235	Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech. <i>Cortex</i> , 2020, 124, 33-43.	1.1	5
236	Neurobehavioral Characteristics of FDG-PET Defined Right-Dominant Semantic Dementia: A Longitudinal Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 17-28.	0.7	5
237	Neurodegeneration of the visual word form area in a patient with word form alexia. <i>Neurology and Clinical Neuroscience</i> , 2021, 9, 359-360.	0.2	5
238	PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 137-137.	0.6	5
239	Natural COA water inhibits mitochondrial ROS-mediated apoptosis through Plk3 downregulation under STZ diabetic stress in pancreatic Î²-cell lines. <i>Biochemistry and Biophysics Reports</i> , 2022, 30, 101247.	0.7	5
240	Amyloid- and tau-PET imaging in a familial prion kindred. <i>Neurology: Genetics</i> , 2018, 4, e290.	0.9	4
241	Non-right handed primary progressive apraxia of speech. <i>Journal of the Neurological Sciences</i> , 2018, 390, 246-254.	0.3	4
242	Longitudinal clinical, neuropsychological, and neuroimaging characterization of a kindred with a 12-octapeptide repeat insertion in <i>i>PRNP</i>: the next generation. <i>Neurocase</i>, 2020, 26, 211-219.</i>	0.2	4
243	Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes. <i>Neurocase</i> , 2021, 27, 212-222.	0.2	4
244	Peripheral Markers of Neurovascular Unit Integrity and Amyloid-Î² in the Brains of Menopausal Women. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 397-405.	1.2	4
245	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphereâ€Predominant Logopenic Progressive Aphasia. <i>Neurology</i> , 2021, 97, e523-e534.	1.5	4
246	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2021, 36, 2669-2675.	2.2	4
247	In vivo imaging and autoradiography in a case of autopsy-confirmed Pick disease. <i>Neurology: Clinical Practice</i> , 2021, 11, 10.1212/CPJ.0000000000000755.	0.8	4
248	Semimechanistic Population Pharmacokinetic Modeling to Investigate Amyloid Beta Trafficking and Accumulation at the BBB Endothelium. <i>Molecular Pharmaceutics</i> , 2021, 18, 4148-4161.	2.3	4
249	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1537-1547.	1.2	4
250	CSF phosphorylated tau as an indicator of subsequent tau accumulation. <i>Neurobiology of Aging</i> , 2022, 117, 189-200.	1.5	4
251	An MRIâ€Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. <i>Journal of Neuroimaging</i> , 2016, 26, 264-268.	1.0	3
252	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. <i>Neurobiology of Aging</i> , 2020, 92, 135-140.	1.5	3

#	ARTICLE	IF	CITATIONS
253	Brain amyloid, cortical thickness, and changes in activities of daily living. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 474-485.	1.7	3
254	Prognostic role of 11C- ϵ -choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy. <i>Prostate</i> , 2022, 82, 41-48.	1.2	3
255	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2022, 143, 571-583.	3.9	3
256	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. <i>Neurology: Genetics</i> , 2017, 3, e201.	0.9	2
257	Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications. <i>Advances in Radiation Oncology</i> , 2019, 4, 79-89.	0.6	2
258	Radiation induced oxidation of [18F]fluorothia fatty acids under cGMP manufacturing conditions. <i>Nuclear Medicine and Biology</i> , 2020, 80-81, 13-23.	0.3	2
259	Polygenic Scores of Alzheimer's Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1615-1625.	1.2	2
260	Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 1044-51.	0.7	1
261	Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-6.	1.2	1
262	3D registration of micro PET-CT for measurable correlates of dyspeptic symptoms in mice. <i>Proceedings of SPIE</i> , 2009, 7262, 72620Z.	0.8	0
263	Reply from Authors re: Alberto Bossi, Nicolas Mottet, Pierre Blanchard. Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time? <i>Eur Urol</i> 2017;71:349-50. <i>European Urology</i> , 2017, 71, 351-352.	0.9	0
264	Your brain scan may be a reflection of your genes. <i>Brain</i> , 2018, 141, 2539-2541.	3.7	0
265	Prior Menopausal Hormone Treatments And Association of Peripheral Markers of Neurovascular Unit Integrity And β -amyloid in The Brains of Menopausal Women. <i>FASEB Journal</i> , 2018, 32, 1b449.	0.2	0